SCLX Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 8.73%

Insider Buying (Last 12 Months): $216,754.96

Insider Selling (Last 12 Months): $0.00

Scilex Insider Trading History Chart

Scilex Share Price & Price History

^$0.61

▼ -0.07 (-10.30%)

As of 11/15/2024 01:00 AM ET

Days: 30 | 90 | 365

I was wrong. Dead wrong.

From Porter & Company | Ad

I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

Here’s the full story for you.

Scilex Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/31/2024	Henry Ji	Insider	Buy	8,888	$0.94	$8,354.72	320,161
10/29/2024	Jaisim Shah	Insider	Buy	32,000	$0.99	$31,680.00	109,333
10/17/2024	Yue Alexander Wu	Director	Buy	20,000	$0.95	$19,000.00	25,000
10/16/2024	Jaisim Shah	Insider	Buy	30,000	$0.99	$29,700.00	77,333
10/16/2024	Stephen Hoi Ma	CFO	Buy	6,700	$0.97	$6,499.00	22,840
5/17/2024	Jay Chun	Director	Buy	57,500	$0.90	$51,750.00	102,500
5/16/2024	Jaisim Shah	Insider	Buy	83,061	$0.84	$69,771.24	98,943

I was wrong. Dead wrong.

From Porter & Company | Ad

I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

Here’s the full story for you.

SEC Filings (Institutional Ownership Changes) for Scilex (NASDAQ:SCLX)

69.67% of Scilex stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Scilex Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
11/15/2024	XTX Topco Ltd	86,335	$80K	0.0%	-18.1%	0.045%
11/15/2024	Jane Street Group LLC	30,164	$28K	0.0%	-89.1%	0.016%
11/15/2024	State Street Corp	7,484,310	$6.92M	0.0%	+0.7%	3.902%
11/15/2024	Janus Henderson Group PLC	534,302	$0.49M	0.0%	+3.5%	0.279%
10/31/2024	Donald L. Hagan LLC	130,792	$0.12M	0.1%	+15.4%	0.068%
8/15/2024	The Manufacturers Life Insurance Company	12,935	$25K	0.0%	N/A	0.007%
8/15/2024	Armistice Capital LLC	11,950,000	$23.06M	0.3%	N/A	6.595%
8/12/2024	XTX Topco Ltd	105,431	$0.20M	0.0%	+321.4%	0.058%
7/26/2024	Bank of New York Mellon Corp	15,815	$31K	0.0%	N/A	0.009%
7/19/2024	Donald L. Hagan LLC	113,292	$0.22M	0.1%	+59.5%	0.063%
5/10/2024	Vanguard Group Inc.	3,988,265	$6.34M	0.0%	+1.4%	2.400%
4/17/2024	Cannon Global Investment Management LLC	25,000	$40K	0.1%	N/A	0.015%
4/9/2024	Collective Family Office LLC	21,950	$35K	0.0%	+68.4%	0.013%
2/13/2024	Tower Research Capital LLC TRC	20,595	$42K	0.0%	-82.7%	0.013%
2/12/2024	Focus Financial Network Inc. ADV	28,257	$58K	0.0%	N/A	0.018%
2/6/2024	Apollon Wealth Management LLC	36,100	$74K	0.0%	-27.8%	0.023%
1/19/2024	Donald L. Hagan LLC	52,343	$0.11M	0.1%	+49.1%	0.033%
12/7/2023	Hudson Bay Capital Management LP	474,683	$0.67M	0.0%	N/A	0.301%
10/24/2023	Bank of New York Mellon Corp	48,459	$68K	0.0%	N/A	0.032%
10/11/2023	Donald L. Hagan LLC	35,098	$49K	0.0%	+39.8%	0.023%
8/14/2023	Casdin Capital LLC	23,512	$0.13M	0.0%	N/A	0.016%
8/11/2023	Deuterium Capital Management LLC	23,994	$96K	0.1%	+25.8%	0.016%
8/10/2023	Ground Swell Capital LLC	12,085	$67K	0.2%	N/A	0.008%
8/7/2023	Wolverine Asset Management LLC	8,224	$46K	0.0%	N/A	0.006%
7/17/2023	Donald L. Hagan LLC	25,098	$0.14M	0.1%	+66.2%	0.017%
7/17/2023	GoalVest Advisory LLC	7,279	$41K	0.0%	N/A	0.005%
6/14/2023	State Board of Administration of Florida Retirement System	14,219	$0.12M	0.0%	N/A	0.010%
5/11/2023	Citigroup Inc.	239,130	$1.96M	0.0%	N/A	0.164%
5/11/2023	E Fund Management Co. Ltd.	31,431	$0.26M	0.0%	N/A	0.022%
5/9/2023	Tower Research Capital LLC TRC	10,538	$86K	0.0%	+1,159.0%	0.007%
5/9/2023	California State Teachers Retirement System	81,066	$0.67M	0.0%	N/A	0.056%
5/9/2023	US Bancorp DE	4,512	$37K	0.0%	N/A	0.003%
5/8/2023	New York Life Investment Management LLC	34,109	$0.28M	0.0%	N/A	0.023%
5/8/2023	Public Employees Retirement Association of Colorado	4,709	$39K	0.0%	N/A	0.003%
5/8/2023	Zurcher Kantonalbank Zurich Cantonalbank	8,554	$70K	0.0%	N/A	0.006%
5/5/2023	Mayo Clinic	42,303	$0.35M	0.3%	N/A	0.029%
5/2/2023	Amalgamated Bank	8,654	$71K	0.0%	N/A	0.006%
4/28/2023	Handelsbanken Fonder AB	11,168	$92K	0.0%	N/A	0.008%
4/27/2023	Arizona State Retirement System	17,904	$0.15M	0.0%	N/A	0.012%
4/18/2023	Donald L. Hagan LLC	15,098	$0.12M	0.1%	N/A	0.010%
4/18/2023	ETF Managers Group LLC	16,589	$0.14M	0.0%	N/A	0.011%
4/14/2023	Raymond James Financial Services Advisors Inc.	18,409	$0.15M	0.0%	N/A	0.013%
4/14/2023	Raymond James & Associates	31,303	$0.26M	0.0%	N/A	0.021%
4/11/2023	Asset Management Resources LLC	19,459	$0.16M	0.1%	N/A	0.013%

Data available starting January 2016

Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California.

Today's Range

Now: $0.61

$0.54

$0.68

50 Day Range

MA: $0.92

$0.61

$1.15

52 Week Range

Now: $0.61

$0.54

$2.63

Volume

4,958,354 shs

Average Volume

1,270,099 shs

Market Capitalization

$116.97 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.14

Who are the company insiders with the largest holdings of Scilex?: Scilex's top insider investors include:
Henry Ji (Insider)
Jaisim Shah (Insider)
Jay Chun (Director)
Yue Alexander Wu (Director)
Stephen Hoi Ma (CFO)
Learn More about top insider investors at Scilex.
Who are the major institutional investors of Scilex?: Scilex's top institutional investors include:
State Street Corp — 3.90%
Janus Henderson Group PLC — 0.28%
Donald L. Hagan LLC — 0.07%
XTX Topco Ltd — 0.05%
Jane Street Group LLC — 0.02%
Learn More about top institutional investors of Scilex stock.
Which major investors are selling Scilex stock?: Within the last quarter, SCLX stock was sold by these institutional investors:
Jane Street Group LLC
XTX Topco Ltd
Which major investors are buying Scilex stock?: During the previous quarter, SCLX stock was acquired by institutional investors including:
State Street Corp
Janus Henderson Group PLC
Donald L. Hagan LLC
Within the last year, these company insiders have bought Scilex stock:
Henry Ji (Insider)
Jaisim Shah (Insider)
Jay Chun (Director)
Yue Alexander Wu (Director)
Stephen Hoi Ma (CFO)
Learn More investors buying Scilex stock.